Golidocitinib for mycosis fungoides, Sézary syndrome and T-LGLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an oral drug called golidocitinib for people with certain types of T-cell lymphoma. It aims to see if the drug can shrink tumors or improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have mycosis fungoides, Sézary syndrome, or T-cell large granular lymphocytic leukemia (T-LGLL).
- You must have tried at least one prior treatment (or have untreated T-LGLL that needs therapy).
- You must be at least 18 years old.
- You must be able to swallow pills.
- You must have adequate kidney, liver, and blood cell counts (certain low counts may be acceptable with doctor's approval).
- You must not be pregnant or breastfeeding, and must agree to use effective birth control during and for several months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a new oral medication called golidocitinib for people who have just been diagnosed with a specific type of T-cell lymphoma and have not had any prior treatment. The goal is to see if this JAK1 inhibitor can help control the disease.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This trial tests a drug called golidocitinib for people with advanced lung cancer who developed serious, hard-to-treat blood-related side effects (like low white blood cells, low platelets, or anemia) from immunotherapy. The goal is to see if golidocitinib can help reverse these side effects without stopping cancer treatment.
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
Hear when a new Mycosis Fungoides/Sezary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.